May 21, 2018. In conclusion, we agree with the USPSTF’s efforts to provide updated recommendations on screening of IPV and abuse based on quality, up-to-date studies. The benefits of screening for IPV for women outweigh the risks, and future studies should allow recommendations to be made for other populations. We agree with the USPSTF draft recommendation on IPV and elder abuse.
Read More »On Health Policy
NCHR Comment on FDA’s Draft Guidance on Developing Drugs for Early Alzheimer’s Disease
May 16, 2018. We support the encouragement of research to develop drugs that would prevent or slow the progression of early Alzheimer’s disease (AD). We support the FDA’s recognition of the importance of efficacy endpoints that demonstrate a clinically meaningful effect on daily function and/or cognition for drug development. It is not appropriate to depend entirely on the use of biomarkers and of limited, narrow measures of neuropsychological performance. It will be important that when these newly developed drugs are evaluated for approval that the FDA maintains high standards for evidence that are based on sound science.
Read More »NCHR Letter to CDC Director Supporting Review of Biopsy Before Hysterectomy or Myomectomy
May 18, 2018. We strongly urge the Centers for Disease Control and Prevention (CDC) to conduct a review to determine the potential benefits of requiring pre-surgical biopsies for women scheduled for hysterectomy or myomectomy (removal of fibroids).
Read More »Letter to Board of Education of Montgomery County on Synthetic Playgrounds
April 23, 2018. Many of the synthetic playground materials being used contain carcinogens, and when children are exposed to those carcinogens day after day, week after week, and year after year, they increase the chances of our children developing cancer, either now or as they get older. That should be adequate reason to not install them in Montgomery County.
Read More »Public Meeting for Patient-Focused Drug Development on Opioid Use Disorder
April 17, 2018. Patients’ perspectives on how opioid use disorder is affecting their health, well-being, and daily lives will help the FDA and drug companies focus on studying outcomes that are most important and clinically relevant for patients.
Read More »